Harbour BioMed, a global biopharmaceutical company focused on advancing innovative antibody-based therapies in immunology and immune-oncology, has announced the online publication of results from the first-in-human Phase I clinical trial …
In 2024, Viatris supplied medications targeting the top ten causes of death worldwide, as identified by the WHO. The company has deliberately focused on expanding access to its diverse portfolio …
